Table 3.
Top 20 most cited papers among economic evaluation publications
| # | Title | Journal | Citations | Years | Cite rate per year |
|---|---|---|---|---|---|
| 1 | Expanded screening for HIV in the United States - An analysis of cost-effectiveness [41] | New England Journal Of Medicine | 369 | 2005 | 28.38 |
| 2 | The cost effectiveness of combination antiretroviral therapy for HIV disease [42] | New England Journal Of Medicine | 349 | 2001 | 20.53 |
| 3 | Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania [43] | Lancet | 250 | 2000 | 13.89 |
| 4 | Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa [44] | Lancet | 196 | 1999 | 10.32 |
| 5 | The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations [45] | Transfusion | 184 | 2003 | 12.27 |
| 6 | Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness [46] | Annals Of Internal Medicine | 169 | 2001 | 9.94 |
| 7 | Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs [47] | Journal Of Acquired Immune Deficiency Syndromes And Human Retrovirology | 167 | 1997 | 7.95 |
| 8 | The cost-effectiveness of preventing AIDS-related opportunistic infections [48] | JAMA-Journal Of The American Medical Association | 163 | 1998 | 8.15 |
| 9 | HIV transmission and the cost-effectiveness of methadone maintenance [49] | American Journal Of Public Health | 134 | 2000 | 7.44 |
| 10 | Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4(+) Cell Count <= 100 Cells/mL Who Start HIV Therapy in Resource-Limited Settings [50] | Clinical Infectious Diseases | 130 | 2010 | 16.25 |
| 11 | Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis [51] | Clinical Infectious Diseases | 125 | 2005 | 9.62 |
| 12 | Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania [52] | Lancet | 124 | 1997 | 5.90 |
| 13 | Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men | American Journal Of Medicine | 121 | 2000 | 6.72 |
| 14 | Positive and negative life events after counselling and testing: the Voluntary HIV-1 Counselling and Testing Efficacy Study [53] | AIDS | 112 | 2001 | 6.59 |
| 15 | Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness [54] | AIDS | 110 | 2008 | 11.00 |
| 16 | Cost-Effectiveness Of Low-Dose Zidovudine Therapy For Asymptomatic Patients With Human-Immunodeficiency-Virus (HIV) Infection [55] | Annals Of Internal Medicine | 109 | 1991 | 4.04 |
| 17 | Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood [56] | Transfusion | 105 | 1997 | 5.00 |
| 18 | The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States [57] | Addiction | 98 | 2001 | 5.76 |
| 19 | The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV [58] | AIDS | 89 | 2008 | 8.90 |
| 20 | Is antenatal syphilis screening still cost effective in sub-Saharan Africa [59] | Sexually Transmitted Infections | 85 | 2003 | 5.67 |